ZYBAN TABLET (EXTENDED-RELEASE)

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

BUPROPION HYDROCHLORIDE

Verfügbar ab:

BAUSCH HEALTH, CANADA INC.

ATC-Code:

N06AX12

INN (Internationale Bezeichnung):

BUPROPION

Dosierung:

150MG

Darreichungsform:

TABLET (EXTENDED-RELEASE)

Zusammensetzung:

BUPROPION HYDROCHLORIDE 150MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

15G/50G

Verschreibungstyp:

Prescription

Therapiebereich:

MISCELLANEOUS ANTIDEPRESSANTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0131140003; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2001-07-04

Fachinformation

_Pr_
_ZYBAN _
_®_
_, Bupropion Hydrochloride _
_ _
_Page 1 of 53 _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ZYBAN
®
Bupropion Hydrochloride
Extended-Release Tablets, 150 mg, for oral use
Mfr. Std.
Smoking Cessation Aid
Bausch Health, Canada Inc.
Date of initial Authorization:
2150 St-Elzear Blvd. West
July 30, 1998
Laval, Quebec
H7L 4A8
Date of Revision:
December 5, 2023
Control #: 276730
ZYBAN
®
is a registered trademark of the GlaxoSmithKline Groups and is used
under license by Bausch
Health, Canada Inc.
_ _
_ _
_Pr_
_ZYBAN_
_®_
_, Bupropion Hydrochloride _
_ Page 2 of 53 _
_ _
RECENT MAJOR LABEL CHANGES
3 SERIOUS WARNINGS AND PRECAUTIONS BOX
12/2021
4.1 Dosing Considerations
12/2023
7 WARNINGS AND PRECAUTIONS, Cardiovascular
12/2023
7 WARNING AND PRECAUTIONS, Immune
12/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
..............................................................................................................................4
1.2
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS
.............................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.......................................................................
5
4
DOSAGE AND ADMINISTRATION
..................